Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Abdurrahman Işıkdoğan


Annals of Oncology (2019) 30 (suppl_5): v591-v601. 10.1093/annonc/mdz259


A. Işıkdoğan1, N. Akdeniz2, M. Küçüköner1, M.A. Kaplan1, Z. Urakçı1, O. Karhan1, Y. Sezgin1, E. Bilen1, S. Ebinç1, F. Teke3, Ş. Laçin4, O. Alan5, O. Ercelep6, F. Yumuk7

Author affiliations

  • 1 Department Of Medical Oncology, Dicle University Medical Faculty, 38000 - Diyarbakır/TR
  • 2 Department Of Medical Oncology, Dicle University Medical Faculty, 21080 - Diyarbakır/TR
  • 3 Department Of Radiation Oncology, Dicle University Medical Faculty, 38000 - Diyarbakır/TR
  • 4 Department Of Medical Oncology, Gazi Yasargil Education and Training Hospital, 21010 - Diyarbakır/TR
  • 5 Department Of Medical Oncology, Marmara University Medical Faculty, 34600 - Istanbul/TR
  • 6 Department Of Medical Oncology, Marmara University Medical Faculty, 34890 - Istanbul/TR
  • 7 Department Of Medical Oncology, Marmara University Medical Faculty, 48000 - Istanbul/TR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2299


The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide regimen related toxicity is high, weekly regimens have been investigating. We aimed to compare the efficacy and safety of different concurrent chemotherapy regimens in the context.


A total of 225 patients with locally advanced, unresectable stage III NSCLC included. Patients who treated with weekly docetaxel-platin (DP), paclitaxel-platin (PP) and standard dose etoposide-platin (EP) chemotherapy regimens were selected and divided to groups for the comparison of toxicity, response rate, progression free survival (PFS) and overall survival (OS) rates.


There was statistically significant difference between overall response rate of each treatment groups (DP: 96,1%, PP: 94% and EP:76.7%, p < 0.001). The median PFS rate of patients who treated with DP, PP and EP was 16, 15 and 13.3 months, respectively (p = 0.435). The median OS of patients treated with DP, PP and EP was 19.2, 29.7 and 28.3 months, respectively (p = 0.092). The rates of adverse events such as nausea, vomiting, neuropathy and anaphylaxis was similar. Grade 1-2 mucositis or esophagitis, anemia, pneumonitis were significantly higher in PP group than other groups. However, hematologic toxicities were higher in the EP group than other groups.Table:


Patients characteristics
DP (N = 102) N(%)PP (N = 50) N(%)EP (N = 73) N(%)P
Median age6164580.038
Gender Male93(91.2)48(96)64(87.7)0.28
Histopathology Squamous cell53(52)31(62)43(58.9)<0.001
Stage IIIB-IIIC65(63.7)31(62)41(56.2)0.59


When the weekly chemotherapy regimens were compared with the standard dose, our study demonstrated similar survival rates but better treatment response rates. Adverse events and toxicity rates were different and depending on the type of chemotherapy regimen used.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Abdurrahman Işıkdogan.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.